
Granisetron hydrochloride
CAS No. 107007-99-8
Granisetron hydrochloride( BRL 43694 )
Catalog No. M10289 CAS No. 107007-99-8
Granisetron Hcl(BRL 43694A) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
25MG | 46 | In Stock |
![]() ![]() |
50MG | 67 | In Stock |
![]() ![]() |
100MG | 116 | In Stock |
![]() ![]() |
200MG | 169 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameGranisetron hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionGranisetron Hcl(BRL 43694A) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.
-
DescriptionGranisetron Hcl(BRL 43694A) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy. IC50 Value: 17uM (GR reduced 5-HT-evoked contractions)(In Vitro):In rat forestomach GR reduced 5-HT-evoked contractions at IC50 17 /- 6 uM. In isolated rabbit heart, GR 0.003-0.03 nM dose-dependently reduced s-HT tachycardia; at high levels GR reduced submaximal and maximal responses to 5-HT.(In Vivo):Leukocyte accumulation was dose-dependently inhibited by granisetron both at 6 and 72 h after induction of inflammation. Granisetron increased PGE(2) level at a lower dose (50 microg/pouch) but higher doses (100 and 200 microg/pouch) inhibited the release. At the same time, TNFalpha production was decreased by the lower dose and increased by higher doses of granisetron in a reciprocal fashion. The GTDS displayed non-inferiority to oral granisetron: complete control was achieved by 60% of patients in the GTDS group, and 65% in the oral granisetron group (treatment difference, -5%; 95% confidence interval, -13-3). Both treatments were well tolerated, the most common adverse event being constipation.
-
In VitroIn rat forestomach GR reduced 5-HT-evoked contractions at IC50 17 /- 6 uM. In isolated rabbit heart, GR 0.003-0.03 nM dose-dependently reduced s-HT tachycardia; at high levels GR reduced submaximal and maximal responses to 5-HT.
-
In VivoLeukocyte accumulation was dose-dependently inhibited by granisetron both at 6 and 72 h after induction of inflammation. Granisetron increased PGE(2) level at a lower dose (50 microg/pouch) but higher doses (100 and 200 microg/pouch) inhibited the release. At the same time, TNFalpha production was decreased by the lower dose and increased by higher doses of granisetron in a reciprocal fashion. The GTDS displayed non-inferiority to oral granisetron: complete control was achieved by 60% of patients in the GTDS group, and 65% in the oral granisetron group (treatment difference, -5%; 95% confidence interval, -13-3). Both treatments were well tolerated, the most common adverse event being constipation.
-
SynonymsBRL 43694
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
Recptor5-HT
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number107007-99-8
-
Formula Weight348.87
-
Molecular FormulaC18H25ClN4O
-
Purity>98% (HPLC)
-
SolubilityEthanol: 1 mg/mL (2.86 mM); Water: 70 mg/mL (200.64 mM); DMSO: 1 mg/mL (2.86 mM)
-
SMILESCl.CN1N=C(C(=O)NC2CC3CCCC(C2)N3C)C2=CC=CC=C12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference



-
NLX-204 hydrochlorid...
NLX-204 hydrochloride is a potent and selective ERK1/2 phosphorylation-preferring serotonin 5 HT1A receptor agonist(pKi = 10.19).NLX-204, displayed high selectivity in the SafetyScreen44 panel (including hERG channel), high solubility, metabolic stability, and Caco-2 penetration and did not block CYP3A4, CYP2D6 isoenzymes, or P-glycoprotein.
-
YL0919
An orally active, dual 5-HT1A agonist and selective serotonin reuptake inhibitor with Ki of 0.19 nM and IC50 of 1.78 nM, respectively.
-
CTEP
CTEP (RO4956371) is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM, shows >1000-fold selectivity over other mGlu receptors.